2000 Pilot Study Grants - Grants 1-21


Funding from The Parkinson Alliance helped to finance the following Parkinson's research. Grantees were selected by scientific review committees of participating organizations. Abstracts and reports are available by clicking the underlined grants.

1. Physiologic Effects of Deep Brain Stimulation in Patients with Parkinson’s Disease--updated 8/2002
Robert Chen, MA, MSc, MBBChir, FRCPC
Toronto Western Hospital, Toronto, Ontario, Canada

2. Intracellular Signaling by Hydrogen Peroxide Via the Thiol Redoxstate
Gerald Cohen, Ph.D.
Mount Sinai School of Medicine, New York, NY

3. Role of the Ferroxidase Ceruloplasmin in Iron-Mediated Free Radical Injury in the Substantia Nigra--updated 8/2002
Samuel David, Ph.D.
Montreal General Hospital Research Institute, Montreal, Quebec, Canada-

4. The Biophysical Approach of the Structural Characterization of Alpha-Synuclein, A Protein Implicated in Parkinson's Disease--updated 8/2002
Ellen W. Doss-Pepe, Ph.D.
University of Medicine and Dentistry of New Jersey (UMDNJ) Robert Wood Johnson Medical School, Piscataway, New Jersey

5. Role of the Stress-Activated Protein Kinase SPAK/JNK Signaling Pathway in the MPTP-Induced Neuronal Death Model of Parkinson’s Disease--updated 8/2002
Richard A. Flavell, Ph.D.
Yale University, New Haven, Connecticut

6. Glutamateric Compensatory Mechanisms Following Injury to the Basal Ganglia--updated 8/2002
Michael W. Jakowec, Ph.D.
University of Southern California, Los Angeles, California

7. Intrinsic Antioxidant Properties of Dopaminergic Neurons--updated 8/2002
Un Jung Kang, M.D.
University of Chicago, Chicago, Illinois

8. Role of Alpha-Synuclein in Synaptic Transmission--updated 8/2002
Seung-Jae Lee, Ph.D.
Brigham & Women's Hospital, Center for Neurologic Diseases
Boston, Massachusetts

9. Expression of Aromatic Amino Acid Decarboxylase and Vesicular Monoamine Transporter Using Lentriviral Vectors to Prevent L-Dopa
Induced Dyskinesias
Stuart Leff, Ph.D.
Emory University, Atlanta, Georgia

10. Central Motor Fatigue in Parkinson’s Disease and the Effect of Levodopa: A Transcranial Magnetic Stimulation Study--updated 8/2002
Jau-Shin Lou, M.D., Ph.D.
Oregon Health Sciences University, Portland, Oregon

11. Characterization of a Regulated Recombinant Adeno-Associated Viral Vector Encoding Human GDNF for the Treatment of Parkinson’s Disease--updated 8/2002
Ronald J. Mandel, Ph.D.
University of Florida College of Medicine, Gainesville, Florida

12. Human Brain Expression of Alpha-Synuclein Messenger RNA in Parkinson's Disease and Related Diseases
David W. Miller, Ph.D.
Massachusetts General Hospital, Boston, Massachusetts

13. GABA-B Receptors and Parkinson’s Disease--updated 8/2002
Yoland Smith, Ph.D.
Emory University, Atlanta, Georgia

14. Effects of Intermittent vs. Continuous L-DOPA on GABAergic Neurons of the Basal Ganglia
--updated 8/2002
Jean-Jacques Soghomonian, Ph.D.
Boston University School of Medicine, Boston, Massachusetts

15. Parkinson’s Disease and FGF Receptor in Gene Therapy--updated 8/2002
Michal K. Stachowiak, Ph.D.
Research Foundation of the State University of New York (SUNY) at Buffalo
Buffalo, New York

16. Anatomical Substrates of Parkinsonian Tremor--updated 8/2002
Iwona Stepniewska, Ph.D.
Vanderbilt University, Nashville, Tennessee

17. Neuromelanin, Iron and Ferritin in Locus Ceruleus as Potential Determinants of Selective Neuronal Vulnerability--updated 8/2002
Luigi Zecca, M.D., Ph.D.
Institute of Advanced Biomedical Technologies—CNR, Segrate, Italy

18. Biochemistry and Immunohistochemistry of Lewy Bodies
Thomas Wisniewski, MD
Institute of Basic Research
Staten Island, NY

19. Dopaminergic Control of Striatal Glutamatergic Functioning
Theodore Lidsky, Ph.D.
Institute of Basic Research
Staten Island, NY

20. Role of Alpha-Synuclein in Neurotransmitter Secretion
Sreeganga Chandra, Ph.D.
University of Texas, S.W. Medical Center, Dallas, Texas

21. Oxidative Stress and BDNF Signaling in Dopaminergic Neurons
Charleen T. Chu, M.D., Ph.D.
University of Pittsburgh, Pittsburgh, Pennsylvania

Continue to 2000 Pilot Study Grants - Grants 22-43
Return to Top

Click for a printer friendly version